ALKS Q1 2023 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena

ALKSAlkermes plc

$5B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$288M+3.2% YoY

Gross Profit

$229M79.8% margin

Operating Income

-$11M-3.8% margin

Net Income

-$42M-14.5% margin

EPS (Diluted)

$-0.25

QoQ Revenue Growth

-5.6%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$28M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$1.9B

Total Liabilities

$917M

Stockholders' Equity

$1.0B

Cash & Equivalents

$321M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$288M	$279M	+3.2%
Gross Profit	$229M	$223M	+2.7%
Operating Income	-$11M	-$27M	+58.7%
Net Income	-$42M	-$36M	-16.6%

Revenue Segments

Product

$215M50%

Vivitrol

$97M23%

Aristada And Aristada Initio

$80M19%

L Y B A L V I

$38M9%